UAE MoHAP Approves First Regional Treatment for Pulmonary Fibrosis Condition

The UAE Ministry of Health and Prevention (MoHAP) has authorized the use of Tyvaso DP (treprostinil) inhalation powder, a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The decision makes the UAE the first nation in the Middle East and North Africa to provide this specific medical intervention for patients suffering from this form of pulmonary fibrosis. Tyvaso DP, developed by United Therapeutics, is a dry powder inhaler designed to improve exercise capacity in patients with PH-ILD. This condition involves scarring of the lung tissue, which restricts oxygen flow and increases pressure in the pulmonary arteries. The approval follows the drug’s clearance by the US Food and Drug Administration (FDA), which categorized it as a breakthrough therapy for this patient population. Regional Regulatory Advancement MoHAP officials confirmed the approval utilized the UAE’s expedited licensing system for innovative medicines. This framework allows for the rapid entry of treatments that have received orphan drug designation from international bodies. By authorizing the treatment, the UAE health authority aims to provide immediate access to medication…